{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.","groups":[{"description":"Participants with recurrent or refractory ewing sarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG000","title":"Phase 2: Cohort 1, Ewing Sarcoma"},{"description":"Participants with recurrent or refractory rhabdomyosarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG001","title":"Phase 2: Cohort 2, Rhabdomyosarcoma"},{"description":"Participants with recurrent or refractory HGG received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG002","title":"Phase 2: Cohort 3, HGG"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SAS included all participants who received at least one dose of study drug (Lenvatinib or Everolimus).","reportingStatus":"POSTED","timeFrame":"From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)","title":"Phase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}